Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression - Trial NCT06269211
Access comprehensive clinical trial information for NCT06269211 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 29 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ruijin Hospital
Timeline & Enrollment
Phase 2
Mar 30, 2024
Jan 31, 2030
Primary Outcome
Major Pathological Response (MPR)
Summary
The study is a prospective, open label, multicenter, single arm Phase II clinical trial,
 aiming to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC
 patients with EGFR mutations and PD-L1 positive expression, providing a novel perspective for
 further improving the prognosis of NSCLC patients. This study will provide valuable
 information for further clinical trials of neoadjuvant Toripalimab and other immune
 checkpoint inhibitors in NSCLC patients with EGFR mutations and PD-L1 positive expression.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06269211
Non-Device Trial